CRISPR-based genome editing in primary human pancreatic islet cells

Bevacqua, Romina J.; Dai, Xiaoqing; Lam, Jonathan Y.; Gu, Xueying; Friedlander, Mollie S. H.; Tellez, Krissie; Miguel Escalada, Irene; Bonàs-Guarch, Silvia; Atla, Goutham; Zhao, Weichen; Kim, Seung Hyun; Dominguez, Antonia A.; Qi, Lei S.; Ferrer, Jorge; MacDonald, Patrick E.; Kim, Seung K.

doi:http://dx.doi.org/10.1038/s41467-021-22651-w

CRISPR-based genome editing in primary human pancreatic islet cells

Citation

Bevacqua RJ, Dai X, Lam JY, Gu X, Friedlander MSH, Tellez K et al. CRISPR-based genome editing in primary human pancreatic islet cells. Nat Commun. 2021 Apr 23;12(1):2397. DOI: 10.1038/s41467-021-22651-w

Abstract

Gene targeting studies in primary human islets could advance our understanding of mechanisms driving diabetes pathogenesis. Here, we demonstrate successful genome editing in primary human islets using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (Cas9). CRISPR-based targeting efficiently mutated protein-coding exons, resulting in acute loss of islet β-cell regulators, like the transcription factor PDX1 and the KATP channel subunit KIR6.2, accompanied by impaired β-cell regulation and function. CRISPR targeting of non-coding DNA harboring type 2 diabetes (T2D) risk variants revealed changes in ABCC8, SIX2 and SIX3 expression, and impaired β-cell function, thereby linking regulatory elements in these target genes to T2D genetic susceptibility. Advances here establish a paradigm for genetic studies in human islet cells, and reveal regulatory and genetic mechanisms linking non-coding variants to human diabetes risk.